Dynavax Technologies Corp (DVAX) - Long-Term Debt to Capital Coefficient

Dynavax Technologies specializes in developing advanced treatments for liver diseases. This price chart illustrates the impact of strict FDA oversight and exclusive patents on the issuer's market position. The company is expanding its presence in the vaccination sector through accelerated treatment regimens, while its financial stability is based on oncology investments funded by profits from its core drug, which reach 0.46.

This metric measures the company's reliance on long-term borrowings by comparing liabilities with a maturity of over one year against the amount of equity. By analyzing the long-term debt-to-equity ratio trend, an investor assesses the financial stability of Dynavax Technologies (DVAX), which remains stable within the defensive vaccine production sector due to the business's low sensitivity to economic cycles.